| 1. |
Kidney disease: improving global outcomes (KDIGO) living kidney donor work group. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation, 2017, 101(Suppl 8S): S1-S109.
|
| 2. |
St Peter WL, Li Q, Liu J, et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol, 2009, 4(2): 354-360.
|
| 3. |
Segev DL, Gentry SE, Melancon JK, et al. Characterization of waitingtimes in a simulation of kidney paired donation. Am J Transplant, 2005, 5: 2448-2455.
|
| 4. |
王显丁, 邱阳, 宋涂润, 等. ABO血型不相容亲属活体肾移植的个体化预处理. 中华器官移植杂志, 2015, 36(8): 449-452.
|
| 5. |
Orandi BJ, Luo X, Massie AB, et al. Survival benefit with kidney transplantsfrom HLA-incompatible live donors. N Engl J Med, 2016, 374: 940-950.
|
| 6. |
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int, 2013: 1-150.
|
| 7. |
Kasiske BL, Anderson-Haag T, Israni AK, et al. A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis, 2015, 66: 114-124.
|
| 8. |
Poggio ED, Braun WE, Davis C. The science of stewardship: due diligence for kidney donors and kidney function in living kidney donation—evaluation, determinants, and implications for outcomes. Clin J Am Soc Nephrol, 2009, 4: 1677-1684.
|
| 9. |
Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and longterm survival following live kidney donation. JAMA, 2010, 303: 959-966.
|
| 10. |
Len O, Garzoni C, Lumbreras C, et al. Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor-derived infections. Clin Microbiol Infect, 2014, 20(Suppl 7): 10-18.
|
| 11. |
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol, 2017, 66: 153-194.
|
| 12. |
U.S. Federal Register. Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. A Notice by the National Institutes of Health on 06/18/2015. Available at: https://www.federalregister.gov/articles/2015/06/18/2015-15034/human-immunodeficiency-virushiv-organ-policy-equity-hope-act-safeguards-and-research-criteria-for.
|
| 13. |
Aguado JM, Torre-Cisneros J, Fortún J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and ClinicalMicrobiology. Clin Infect Dis, 2009, 48: 1276-1284.
|
| 14. |
Nalesnik MA,Woodle ES, Dimaio JM, et al. Donor-transmittedmalignancies in organ transplantation: assessment of clinical risk. Am J Transplant, 2011, 11: 1140-1147.
|
| 15. |
Kanaan N, Devuyst O, Pirson Y. Renal transplantation in autosomal dominant polycystic kidney disease. Nat Rev Nephrol, 2014, 10: 455-465.
|
| 16. |
Garg AX, Nevis IF, McArthur E, et al. Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med, 2015, 372: 124-133.
|
| 17. |
Janki S, Verver D, Klop KW, et al. Vascular management during live donor nephrectomy: an online survey among transplant surgeons. Am J Transplant, 2015, 15: 1701-1707.
|
| 18. |
Manyalich M, Ricart A, Martinez I, et al. EULID project: European living donation and public health. Transplant Proc, 2009, 41: 2021-2024.
|
| 19. |
Manyalich M, Menjivar A, Yucetin L, et al. Living donor psychosocial assessment/follow-up practices in the partners' countries of the ELIPSY project. Transplant Proc, 2012, 44: 2246-2249.
|
| 20. |
Scientific Registry of Transplant Recipients. The Living Donor Collective: SRTR to Launch a Pilot Project to Create a Registry of Living Donors. Available at: https://www.srtr.org/news-media/news/news-items/news/.
|
